Sterling Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Sterling Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$12.7K	Sell	890 -34	-4%	-$442	﹤0.01%	2409
2026 Q2	$12.3K	Sell	924 -541	-37%	-$5.27K	﹤0.01%	2111
2026 Q1	$13.6K	Sell	1,465 -861	-37%	-$7.49K	﹤0.01%	2212
2025 Q4	$17.4K	Sell	2,326 -445	-16%	-$4.51K	﹤0.01%	2305
2025 Q3	$24.1K	Buy	2,771 +1,687	+156%	+$10.1K	﹤0.01%	2057
2025 Q2	$4.02K	Buy	1,084 +778	+254%	+$2.74K	﹤0.01%	2630
2025 Q1	$988	Sell	306 -329	-52%	-$1.55K	﹤0.01%	2822
2024 Q4	$3.54K	Buy	635 +546	+613%	+$4.28K	﹤0.01%	2596
2024 Q3	$962	Buy	+89	New	+$1.48K	﹤0.01%	2550

Other funds holding FDMT

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Sterling Capital Management's FDMT Position: Q3 2026 in Review

Sterling Capital Management reduced its 4D Molecular Therapeutics (FDMT) stake by 3.7% in Q3 2026, selling an estimated $442 and leaving 890 shares worth $12.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2409.

Sterling Capital Management first reported a position in FDMT in Q3 2024 and has held it in 9 quarters since. The position peaked at $24.1K in Q3 2025. 110 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

Sterling Capital Management held 890 shares of 4D Molecular Therapeutics worth $12.7K as of Q3 2026.
Sterling Capital Management sold 34 4D Molecular Therapeutics shares in Q3 2026, an estimated $442.
4D Molecular Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2409 holding.
Sterling Capital Management first reported a position in 4D Molecular Therapeutics in Q3 2024 and has held it in 9 quarters since.
Sterling Capital Management's 4D Molecular Therapeutics position peaked at $24.1K in Q3 2025.
110 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.